US2018346560A1PendingUtilityA1
Method for modulating appetite
Assignee: ST VINCENTS HOSPITAL SYDNEY LTDPriority: Apr 13, 2004Filed: Jun 11, 2018Published: Dec 6, 2018
Est. expiryApr 13, 2024(expired)· nominal 20-yr term from priority
A61P 43/00A61P 3/04A61P 3/00A61P 1/04A61P 1/14C07K 16/24G01N 2800/02A61K 2039/505A61K 38/19C07K 16/22A61K 38/1709G01N 2800/303C07K 2317/24C07K 2317/76
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1-modulating agent, wherein said agent increases or decreases the amount of MIC-1 present in said subject, or inhibits or enhances the biological activity of MIC-1 present in said subject.
Claims
exact text as granted — not AI-modified1 . A method for increasing appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1 inhibiting agent optionally in admixture with a pharmacologically-acceptable carrier and/or excipient.
2 . A method according to claim 1 , wherein said MIC-1 inhibiting agent is an agent which decreases the amount of endogenous MIC-1 in said subject.
3 . A method according to claim 2 wherein said agent is selected from the group consisting of anti-MIC-1 antibodies or fragments thereof, catalytic and inhibitory molecules targeted against the MIC-1 gene and inhibitors of MIC-1 transcription or translation.
4 . A method according to claim 1 , wherein said MIC-1 inhibiting agent is an agent which inhibits the activity of endogenous MIC-1 in said subject.
5 . A method according to claim 4 , wherein said agent is selected from the group consisting of anti-MIC-1 antibodies or fragments thereof, soluble extra-cytoplasmic receptor domains of MIC-1 receptors, soluble molecules or matrix-associated proteins that bind to MIC-1 and peptide, peptide mimetic or small organic molecule inhibitors of MIC-1 binding to its receptor.
6 . A method according to claim 1 wherein said MIC-1 inhibiting agent is a humanised monoclonal anti-MIC-1 antibody.
7 . A method according to claim 1 , wherein the subject is suffering from decreased appetite and/or weight loss associated with advanced cancer.
8 . A method according to claim 1 , wherein the subject is suffering from decreased appetite and/or weight loss associated with inflammatory disease.
9 . A method according to claim 8 , wherein the subject is suffering from rheumatoid arthritis.
10 . A method according to claim 1 , wherein the subject is suffering from decreased appetite and/or weight loss associated with an epithelial cancer.
11 . A method according to claim 10 , wherein the subject is suffering from an epithelial cancer selected from breast, prostate, colonic, rectal, bladder and pancreatic cancer.
12 . A method according to claim 1 , wherein the subject is suffering from decreased appetite and/or weight loss associated with a disease, condition or treatment characterised by MIC-1 over-expression.
13 . A method according to claim 12 , wherein the subject is suffering from injury, inflammation or stress.
14 . A method according to claim 1 , wherein the subject is suffering from decreased appetite and/or weight loss associated with radiotherapy or chemotherapy.Join the waitlist — get patent alerts
Track US2018346560A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.